| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 6, 2025 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $2.00 → $5.00 | Buy | HC Wainwright & Co. |
Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today - May 14, 2025, at 11:00 AM ESTCRANBURY, N.J., May 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2025. "We had a strong quarter operationally, with significant progress across both our obesity and ocular pipelines," said Carl Spana, Ph.D., Pre
Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory pathways, suppress angiogenesis, and preserve retinal structure and functionTopical and systemic administration options enable potential for earlier intervention than current therapiesResults support the continued development of PL9654 and PL9655 for the treatment of diabetic retinopathy (DR)CRANBURY, N.J., May 9, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new
Company Transitioned onto the OTC Pink CRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the "Series F Warrants"), Series G warrants to purchase up to 7,324,119 shares of common stock (the "Series G Warrants"), and Seri
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
424B4 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -
CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q
Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a
SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)